Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks, has completed a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, strengthening its central nervous system (CNS) platform with new neurotherapeutic compounds and delivery technologies. The acquisition is designed to address a key challenge in neurological disease treatment, particularly in conditions such as Alzheimer's disease, where the blood-brain barrier (BBB) limits drug access to the brain.

The expanded portfolio introduces complementary CNS delivery approaches, including a BBB-crossing prodrug system and a nose-to-brain (N2B) pathway that bypasses the BBB via olfactory and trigeminal routes. These technologies will be integrated into Lunai Bioworks IP, Inc., a wholly owned subsidiary, to support both standalone and combination therapies. The platform also aligns with the company’s AI-driven patient stratification strategy and expands potential applications across neurological diseases, biodefense, and 505(b)(2) regulatory pathways.

Lunai’s Augusta platform further enhances this strategy by stratifying patients based on biological drivers rather than traditional disease categories. This is expected to improve candidate selection and support the development of targeted therapies for specific patient subgroups, including those affected by acute toxic or environmental exposures.

“This transaction integrates complementary CNS delivery technologies to address longstanding challenges in neurological drug development,” said CEO David Weinstein, noting that the move also opens new opportunities for partnerships, licensing, and non-dilutive funding.